Brief: Xintela Reports Results From Preclinical Ards Study And Grant Of SEK 2.3 Mln

Xintela AB

06/04/2021 07:57

April 6 (Reuters) - Xintela AB  XINT.ST :
    * XINTELA REPORTS POSITIVE RESULTS FROM PRECLINICAL ARDS
STUDY AND
NEW GRANT OF 2.3 MILLION SEK
    * NEW GRANT FROM SWELIFE/VINNOVA TO FURTHER INVESTIGATE
MECHANISM
OF ACTION OF XSTEM IN PRECLINICAL ARDS MODEL
    * RESULTS ALSO INDICATED IMMUNOMODULATORY AND
ANTI-INFLAMMATORY
EFFECT OF STEM CELLS
    * RESULTS OF STUDY DEMONSTRATE POTENTIAL OF COMPANY'S STEM
CELL
PRODUCT XSTEM® IN TREATMENT OF ARDS
    * RESULTS CONFIRM THERAPEUTIC EFFECT OF XSTEM

Source text for Eikon:  ID:nBQNsz352 
Further company coverage:  XINT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))